akusherstvoObstetrics, Gynecology and ReproductionАкушерство, Гинекология и Репродукция2313-73472500-3194IRBIS LLC10.17749/2313-7347/ob.gyn.rep.2024.590akusherstvo-2292Research ArticleLECTUREЛЕКЦИЯCOVID-19 and systemic thrombotic syndromesCOVID-19 и системные тромботические синдромыhttps://orcid.org/0000-0001-7415-4633МакацарияА. Д.MakatsariyaA. D.

Макацария Александр Давидович, д.м.н., проф., академик РАН

119991 Москва, Трубецкая ул., д. 8, стр. 2

Scopus Author ID: 57222220144. WoS ResearcherID: M-5660-2016

Alexander D. Makatsariya, MD, Dr Sci Med, Prof., Academician of RAS

8 bldg. 2, Trubetskaya Str., Moscow 119991

Scopus Author ID: 57222220144. WoS ResearcherID: M-5660-2016

gemostasis@mail.ruФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияSechenov UniversityRussian Federation202410012025186908918Copyright © Makatsariya A.D., 20252025Макацария А.Д.Makatsariya A.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gynecology.su/jour/article/view/2292

COVID-19 is one of the most dangerous diseases of the current decade that has significantly affected the overall morbidity, mortality, quality of health and life of global population. Among multiple early and late post-COVID complications observed in patients with a new coronavirus infection, perhaps the main place is held by thrombosis. The significant role of microthrombosis, disseminated intravascular coagulation, thrombotic angiopathies in COVID-19 pathogenesis is noted. The accumulated data from clinical studies and the presented expert opinions made it possible to establish the significance of the "immunothrombosis–NETosis–thromboinflammation" relationship in the pathological effects caused by SARS-CoV-2 virus, as well as to reveal the mechanisms underlying formation of thrombotic syndromes mediated by anticoagulant therapy and vaccination. The information obtained about hemostasis disorders allows to move deeper into understanding the long-term sequelae in COVID-19 convalescent patients.

COVID-19 является одним из грозных заболеваний текущего десятилетия, значительно повлиявшее на общую заболеваемость, смертность, качество здоровья и жизни населения планеты. Среди множества осложнений, наблюдаемых у пациентов с новой коронавирусной инфекцией, пожалуй, главное место в структуре постковидных ранних и поздних осложнений занимают тромбозы. Отмечена значимая роль микротромбозов, диссеминированного внутрисосудистого свертывания, тромботических ангиопатий в патогенезе COVID-19. Накопленные данные клинических исследований и представленные экспертные мнения позволили установить значимость связи «иммунотромбоз–нетоз–тромбовоспаление» в патологических эффектах, вызванных вирусом SARS-CoV-2, а также раскрыть механизмы формирования тромботических синдромов, опосредованных антикоагулянтной терапией и вакцинацией. Полученные сведения об особенностях нарушений системы гемостаза позволяют продвинуться в понимании отдаленных последствий среди пациентов, перенесших COVID-19.

COVID-19тромбозтромботические синдромыиммунотромбозтромботический штормнетоздиссеминированное внутрисосудистое свертываниевакцин-индуцированная иммунная тромботическая тромбоцитопенияCOVID-19thrombosisthrombotic syndromesimmunothrombosisthrombotic stormNETosisdisseminated intravascular coagulationvaccine-induced immune thrombotic thrombocytopeniaReferencesWHO Health Emergencies Programme. Number of COVID-19 cases reported to WHO (cumulative total). WHO COVID-19 dashboard. World Health Organization, 2024. Режим доступа: https://data.who.int/dashboards/covid19/cases. [Дата обращения: 25.11.2024].WHO Health Emergencies Programme. Number of COVID-19 cases reported to WHO (cumulative total). WHO COVID-19 dashboard. World Health Organization, 2024. Available at: https://data.who.int/dashboards/covid19/cases. [Accessed: 25.11.2024].Leung T.Y.M., Chan A.Y.L., Chan E.W. et al. Short- and potential long-term adverse health outcomes of COVID-19: a rapid review. Emerg Microbes Infect. 2020;9(1):2190-9. https://doi.org/10.1080/22221751.2020.1825914.Leung T.Y.M., Chan A.Y.L., Chan E.W. et al. Short- and potential long-term adverse health outcomes of COVID-19: a rapid review. Emerg Microbes Infect. 2020;9(1):2190-9. https://doi.org/10.1080/22221751.2020.1825914.Jenner W.J., Kanji R., Mirsadraee S. et al. Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review. J Thromb Thrombolysis. 2021;51(3):595-607. https://doi.org/10.1007/s11239-021-02394-7.Jenner W.J., Kanji R., Mirsadraee S. et al. Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review. J Thromb Thrombolysis. 2021;51(3):595-607. https://doi.org/10.1007/s11239-021-02394-7.Lillicrap D., Morrissey J.H. 2020 - Year of COVID-19. J Thromb Haemost. 2020;18(9):2081. https://doi.org/10.1111/jth.15041.Lillicrap D., Morrissey J.H. 2020 - Year of COVID-19. J Thromb Haemost. 2020;18(9):2081. https://doi.org/10.1111/jth.15041.Cattaneo M., Bertinato E.M., Birocchi S. et al. Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Thromb Haemost. 2020;120(8):1230-2. https://doi.org/10.1055/s-0040-1712097.Cattaneo M., Bertinato E.M., Birocchi S. et al. Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Thromb Haemost. 2020;120(8):1230-2. https://doi.org/10.1055/s-0040-1712097.Ackermann M., Verleden S.E., Kuehnel M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120-8. https://doi.org/10.1056/NEJMoa2015432.Ackermann M., Verleden S.E., Kuehnel M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120-8. https://doi.org/10.1056/NEJMoa2015432.Макацария А.Д., Бицадзе В.О., Хизроева Д.Х. Катастрофический антифосфолипидный синдром и тромботический "шторм". Сибирский медицинский журнал. 2010;25(4-2):118-23.Makatsariya A.D., Bitsadze V.O., Khizroeva J.Kh. Catastrophic antiphospholipid syndrome and thrombotic "storm". [Katastroficheskij antifosfolipidnyj sindrom i tromboticheskij "shtorm"]. Sibirskij medicinskij zhurnal. 2010;25(4-2):118-23. (In Russ.).Макацария А.Д., Григорьева К.Н., Мингалимов М.А. и др. Коронавирусная инфекция (COVID-19) и синдром диссеминированного внутрисосудистого свертывания. Акушерство, Гинекология и Репродукция. 2020;14(2):123-31. https://doi.org/10.17749/2313-7347.132.Makatsariya A.D., Grigoreva K.N., Mingalimov M.A. et al. Coronavirus disease (COVID-19) and disseminated intravascular coagulation syndrome. [Koronavirusnaya infekciya (COVID-19) i sindrom disseminirovannogo vnutrisosudistogo svertyvaniya]. Obstetrics, Gynecology and Reproduction. 2020;14(2):123-31. (In Russ.). https://doi.org/10.17749/2313-7347.132.Popescu N.I., Lupu C., Lupu F. Disseminated intravascular coagulation and its immune mechanisms. Blood. 2022;139(13):1973-86. https://doi.org/10.1182/blood.2020007208.Popescu N.I., Lupu C., Lupu F. Disseminated intravascular coagulation and its immune mechanisms. Blood. 2022;139(13):1973-86. https://doi.org/10.1182/blood.2020007208.Iba T., Levi M., Thachil J., Levy J.H. Disseminated intravascular coagulation: the past, present, and future considerations. Semin Thromb Hemost. 2022;48(8):978-87. https://doi.org/10.1055/s-0042-1756300.Iba T., Levi M., Thachil J., Levy J.H. Disseminated intravascular coagulation: the past, present, and future considerations. Semin Thromb Hemost. 2022;48(8):978-87. https://doi.org/10.1055/s-0042-1756300.Makatsariya A.D., Slukhanchuk E.V., Bitsadze V.O. et al. Thrombotic microangiopathy, DIC-syndrome and COVID-19: link with pregnancy prothrombotic state. J Matern Fetal Neonatal Med. 2022;35(13):2536-44. https://doi.org/10.1080/14767058.2020.1786811.Makatsariya A.D., Slukhanchuk E.V., Bitsadze V.O. et al. Thrombotic microangiopathy, DIC-syndrome and COVID-19: link with pregnancy prothrombotic state. J Matern Fetal Neonatal Med. 2022;35(13):2536-44. https://doi.org/10.1080/14767058.2020.1786811.Wyrick-Glatzel J. Thrombotic thrombocytopenic purpura and ADAMTS-13: new insights into pathogenesis, diagnosis, and therapy. Laboratory Medicine. 2004;35(12):733-9. https://doi.org/10.1309/77KRKLJW0EA75T2R.Wyrick-Glatzel J. Thrombotic thrombocytopenic purpura and ADAMTS-13: new insights into pathogenesis, diagnosis, and therapy. Laboratory Medicine. 2004;35(12):733-9. https://doi.org/10.1309/77KRKLJW0EA75T2R.Tsai H.M. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol. 2010;91(1):1-19. https://doi.org/10.1007/s12185-009-0476-1.Tsai H.M. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol. 2010;91(1):1-19. https://doi.org/10.1007/s12185-009-0476-1.Макацария А.Д., Хизроева Д.Х., Шенфельд И. и др. Фактор фон Виллебранда и миелопероксидаза как лабораторные предикторы выживаемости при тяжелом течении COVID-19. Вестник Российской академии медицинских наук. 2022;77(3):189-98. https://doi.org/10.15690/vramn2094.Makatsariya A.D., Khizroeva J.Kh., Schoenfeld I. et al. Von Willebrand factor and myeloperoxidase as laboratory predictive markers of in-hospital survival in severe COVID-19 patients. [Faktor fon Villebranda i mieloperoksidaza kak laboratornye prediktory vyzhivaemosti pri tyazhelom techenii COVID-19]. Vestnik Rossijskoj akademii medicinskih nauk. 2022;77(3):189-98. (In Russ.). https://doi.org/10.15690/vramn2094.Бицадзе В.О., Хизроева Д.Х., Гри Ж.-К. и др. Патогенетическое и прогностическое значение воспаления и нарушений в оси ADAMTS-13/vWF у больных тяжелой формой COVID-19. Акушерство, Гинекология и Репродукция. 2022;16(3):228-43. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.327.Bitsadze V.O., Khizroeva J.Kh., Gris J.-C. et al. Pathogenetic and prognostic significance of inflammation and altered ADAMTS-13/vWF axis in patients with severe COVID-19. [Patogeneticheskoe i prognosticheskoe znachenie vospaleniya i narushenij v osi ADAMTS-13/vWF u bol'nyh tyazheloj formoj COVID-19]. Obstetrics, Gynecology and Reproduction. 2022;16(3):228-43. (In Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.327.Ortel T.L., Kitchens C.S., Erkan D. et al. Clinical causes and treatment of the thrombotic storm. Expert Rev Hematol. 2012;5(6):653-9. https://doi.org/10.1586/ehm.12.56.Ortel T.L., Kitchens C.S., Erkan D. et al. Clinical causes and treatment of the thrombotic storm. Expert Rev Hematol. 2012;5(6):653-9. https:// doi.org/10.1586/ehm.12.56.Libby P., Simon D.I. Inflammation and thrombosis: the clot thickens. Circulation. 2001;103(13):1718-20. https://doi.org/10.1161/01.cir.103.13.1718.Libby P., Simon D.I. Inflammation and thrombosis: the clot thickens. Circulation. 2001;103(13):1718-20. https://doi.org/10.1161/01.cir.103.13.1718.Tanguay J.F., Geoffroy P., Dorval J.F., Sirois M.G. Percutaneous endoluminal arterial cryoenergy improves vascular remodelling after angioplasty. Thromb Haemost. 2004;92(5):1114-21. https://doi.org/10.1160/TH04-06-0336.Tanguay J.F., Geoffroy P., Dorval J.F., Sirois M.G. Percutaneous endoluminal arterial cryoenergy improves vascular remodelling after angioplasty. Thromb Haemost. 2004;92(5):1114-21. https://doi. org/10.1160/TH04-06-0336.Blair P., Rex S., Vitseva O. et al. Stimulation of Toll-like receptor 2 in human platelets induces a thromboinflammatory response through activation of phosphoinositide 3-kinase. Circ Res. 2009;104(3):346-54. https://doi.org/10.1161/CIRCRESAHA.108.185785.Blair P., Rex S., Vitseva O. et al. Stimulation of Toll-like receptor 2 in human platelets induces a thromboinflammatory response through activation of phosphoinositide 3-kinase. Circ Res. 2009;104(3):346-54. https://doi.org/10.1161/CIRCRESAHA.108.185785.Schrottmaier W.C., Assinger A. The concept of thromboinflammation. Hamostaseologie. 2024;44(1):21-30. https://doi.org/10.1055/a-2178-6491.Schrottmaier W.C., Assinger A. The ooncept of thromboinflammation. Hamostaseologie. 2024;44(1):21-30. https://doi.org/10.1055/a-2178-6491.Ammollo C.T., Semeraro F., Bison E. et al. Patients with antiphospholipid syndrome display a marked resistance to the profibrinolytic activity of anticoagulants. ISTH Academy, December 2, 2024. Режим доступа: https://academy.isth.org/isth/2020/milan/297022/mario.colucci.patients.with.antiphospholipid.syndrome.display.a.marked.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dammollo. [Дата обращения: 25.11.2024].Ammollo C.T., Semeraro F., Bison E. et al. Patients with antiphospholipid syndrome display a marked resistance to the profibrinolytic activity of anticoagulants. ISTH Academy, December 2, 2024. Available at: https://academy.isth.org/isth/2020/milan/297022/mario.colucci.patients.with.antiphospholipid.syndrome.display.a.marked.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dammollo. [Accessed: 25.11.2024].Pavord S., Hunt B.J., Horner D. et al.; Guideline Committee. Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance. BMJ. 2021;375:n2195. https://doi.org/10.1136/bmj.n2195.Pavord S., Hunt B.J., Horner D. et al.; Guideline Committee. Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance. BMJ. 2021;375:n2195. https://doi.org/10.1136/bmj.n2195.Warkentin T. Anti-PF4 antibody-mediated thrombosis disorders: HIT, aHIT, SpHIT. ISTH Academy, December 3, 2024. Режим доступа: https://academy.isth.org/isth/2024/isth-2024-congress/4137061/theodore.28ted29.warkentin.anti-pf4.antibody-mediated.thrombosis.disorders.hit.html?f=menu%3D3%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D1%2Atopic%3D21415. [Дата обращения: 25.11.2024].Warkentin T. Anti-PF4 antibody-mediated thrombosis disorders: HIT, aHIT, SpHIT. ISTH Academy, December 3, 2024. Available at: https://academy.isth.org/isth/2024/isth-2024-congress/4137061/theodore.28ted29.warkentin.anti-pf4.antibody-mediated.thrombosis.disorders.hit.html?f=menu%3D3%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D1%2Atopic%3D21415. [Accessed: 25.11.2024].Warkentin T.E. Platelet-activating anti-PF4 disorders: An overview. Semin Hematol. 2022;59(2):59-71. https://doi.org/10.1053/j.seminhematol.2022.02.005.Warkentin T.E. Platelet-activating anti-PF4 disorders: An overview. Semin Hematol. 2022;59(2):59-71. https://doi.org/10.1053/j.seminhematol.2022.02.005.Nicolai L., Kaiser R., Stark K. Thromboinflammation in long COVID - the elusive key to postinfection sequelae? J Thromb Haemost. 2023;21(8):2020-31. https://doi.org/10.1016/j.jtha.2023.04.039.Nicolai L., Kaiser R., Stark K. Thromboinflammation in long COVID - the elusive key to postinfection sequelae? J Thromb Haemost. 2023;21(8):2020-31. https://doi.org/10.1016/j.jtha.2023.04.039.

The authors declare that there are no conflicts of interest present.